Boston Scientific said net sales for 2024 were $16.747 billion, an increase of $2.507 billion or 17.6% compared to 2023 net sales of $14.240 billion, with organic net sales growth of 16.4%.

10-KAnnual reportFiled Feb 18, 2025Period of report Dec 31, 2024Summary published (UTC) Oct 11, 2026

Key points

AI summary

Boston Scientific said net sales for 2024 were $16.747 billion, an increase of $2.507 billion or 17.6% compared to 2023 net sales of $14.240 billion, with organic net sales growth of 16.4%.
The company said net income attributable to Boston Scientific common stockholders in 2024 was $1.853 billion, or $1.25 per diluted share, and adjusted net income attributable to Boston Scientific common stockholders, excluding items management excluded for purposes of assessing operating performance, was $3.725 billion, or $2.51 per share.
Boston Scientific said that in 2024, investing activities included cash payments of $4.640 billion for acquisitions of businesses, net of cash acquired, primarily related to the acquisitions of Axonics and Silk Road Medical, and that in 2024 it raised $2.145 billion in net proceeds from the registered public offering of Eurobonds, net of investor discounts and issuance costs.
The company said that as of December 31, 2024, it had $414 million of unrestricted cash and cash equivalents on hand, the 2021 Revolving Credit Facility had no amounts outstanding, and it was in compliance with its financial covenants.

Key figures

Fiscal year ended December 31, 2024

Revenue: $16.7B
Operating income: $2.6B
Net income: $1.8B
EPS: $1.25
Gross profit: $11.5B
Operating cash flow: $3.4B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

2024 Net Sales of $16.747 billion

Boston Scientific said net sales for 2024 were $16.747 billion, an increase of $2.507 billion or 17.6% compared to 2023 net sales of $14.240 billion, with organic net sales growth of 16.4%.

Source · Based on the MD&A text of the filing

GAAP Net Income and Adjusted Net Income

The company said net income attributable to Boston Scientific common stockholders in 2024 was $1.853 billion, or $1.25 per diluted share, and adjusted net income attributable to Boston Scientific common stockholders, excluding items management excluded for purposes of assessing operating performance, was $3.725 billion, or $2.51 per share.

Source · Based on the MD&A text of the filing

Acquisition Cash Payments and Eurobonds Offering

Boston Scientific said that in 2024, investing activities included cash payments of $4.640 billion for acquisitions of businesses, net of cash acquired, primarily related to the acquisitions of Axonics and Silk Road Medical, and that in 2024 it raised $2.145 billion in net proceeds from the registered public offering of Eurobonds, net of investor discounts and issuance costs.

Source · Based on the MD&A text of the filing

Liquidity and Financial Covenant Compliance

The company said that as of December 31, 2024, it had $414 million of unrestricted cash and cash equivalents on hand, the 2021 Revolving Credit Facility had no amounts outstanding, and it was in compliance with its financial covenants.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.